AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02626715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myeloablative Conditioning Regimen
Description: Campath (alemtuzumab) - drug class: monoclonal antibody Thiotepa (triethylenethiophosphoramide) - drug class: cytotoxic agent Fludara (fludarabine) - drug class: antimetabolite Busulfex (busulfan) - drug class: alkylating agent
Study NCT00319878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Oral loading dose followed by a once daily dose:~* Cohort 1: Loading Dose - 1.2 mg; Daily Dose - 0.4 mg~* Cohort 2: % Dose Increase - 100%; Loading Dose - 2.4 mg; Daily Dose - 0.8 mg~* Cohort 3: % Dose Increase - 67%; Loading Dose - 3.9 mg; Daily Dose - 1.3 mg~* Cohort 4: % Dose Increase - 50%; Loading Dose - 6.0 mg; Daily Dose - 2.0 mg
Study NCT00319878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Dose of 5 mg/kg divided as a twice daily oral dose
Study NCT00761332 — intervention group
Intervention type: DRUG
Intervention: teriparatide
Description: treatment will be prescribed according to usual standard of care
Study NCT00761332 — intervention group
Intervention type: DRUG
Intervention: antiresorptives
Description: treatment will be prescribed according to usual standard of care
Study NCT02552706 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics
Description: Administration of mixture probiotics 500mg by mouth, one time or divided into 2-4 times depends on the feeding volume until to 36 weeks post menstrual age.
Study NCT02552706 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: glucose solution
Description: Administration of 1 mL of a 5% glucose solution by mouth, one time or divided into 2-4 times depends on the feeding volume until to 36 weeks post menstrual age.
Study NCT03436797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK002
Description: AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).
Study NCT04196517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Tool, PALS
Description: The Patient Activated Learning System is a free, health education platform.
Study NCT04196517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WebMD
Description: WebMD is a widely used educational platform for health information.
Study NCT04582409 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo concentrate solution for injection via intravenous infusion
Study NCT00966082 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic band ligation
Description: Perform EBL until esophageal varices are eradicated, and then follow-up endoscopy with 3-6 months interval
Study NCT00966082 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic band ligation+Propranolol
Description: Perform EBL same as EBL group. In addition, take propranolol to reduce 25% in HR or HR ≤55/min
Study NCT02305667 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Macintosh
Description: double lumen tube intubation using the Macintosh laryngoscope
Study NCT02305667 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope®
Description: double lumen tube intubation using the Glidescope® videolaryngoscope. The distal portion of a left-sided DLT will be angulated to the right concealing the distal orifice of the tracheal lumen. The DLT will be advanced directly through the vocal cords after initial 90° clockwise rotation, the stylet will be removed, and then the DLT will be advanced gently while rotating in a 180° couterclockwise direction
Study NCT02305667 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq®
Description: double lumen tube intubation using the Airtraq® videolaryngoscope.
Study NCT00690768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravitreal bevacizumab (1.5 mg; 0,06 ml) 1 week after baseline; pars plana vitrectomy 3 weeks after baseline
Study NCT00690768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pars plana vitrectomy
Description: pars plana vitrectomy 3 weeks after baseline
Study NCT00690768 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pars plana vitrectomy
Description: pars plana vitrectomy 3 weeks after baseline
Study NCT03230968 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integral Action Program for Respiration
Study NCT02868307 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Answering questionnaire
Study NCT01074307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Bisoprolol
Description: Bisoprolol tablet (Concor) will be administered orally at a starting dose of 1.25 milligram (mg) once daily for 2 weeks. The dose will be further escalated from 1.25 mg to 2.5 mg once daily after 2 weeks and will be administered up to 26 weeks, only if the previous administered dose is well tolerated. If the subject could not tolerate the increased dose, then the last tolerated dose will be maintained up to 26 weeks.
Study NCT01074307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Bisoprolol
Description: Bisoprolol tablet (Concor) will be administered orally at a starting dose of 3.75 mg once daily for 2 weeks. The dose will be subsequently increased to 5 mg, 7.5 mg, or 10 mg once daily every two weeks and will be administered up to 26 weeks, only if the previous administered dose is well tolerated. If the subject could not tolerate the increased dose, then the last tolerated dose will be maintained up to 26 weeks.
Study NCT02037373 — intervention group
Intervention type: BIOLOGICAL
Intervention: Octaplas™
Description: Octaplas™ infusion solution for IV administration as prescribed by the treating physician.
Study NCT02037373 — intervention group
Intervention type: BIOLOGICAL
Intervention: Plasma
Description: Plasma as prescribed by the treating physician.
Study NCT01120600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odanacatib
Description: One 50 mg tablet once weekly
Study NCT01120600 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Odanacatib
Description: One 50 mg tablet once weekly
Study NCT01120600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 5600 IU of open-label Vitamin D3 once weekly
Study NCT01120600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: 5600 IU of open-label Vitamin D3 once weekly
Study NCT01120600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Description: Sufficient amount of open-label calcium carbonate so that daily calcium intake from both dietary and supplementary sources in approximately 1200 mg
Study NCT01120600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium carbonate
Description: Sufficient amount of open-label calcium carbonate so that daily calcium intake from both dietary and supplementary sources in approximately 1200 mg
Study NCT02964065 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live-Attenuated influenza Vaccine(LAIV)
Study NCT02964065 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03134417 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D and magnesium
Description: Daily vitamin D and magnesium supplements are given to participants daily for 12 weeks.
Study NCT03134417 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Daily vitamin D supplements are given to participants daily for 12 weeks.
Study NCT03134417 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily placebo are given to participants daily for 12 weeks.
Study NCT02123069 — intervention group
Intervention type: DEVICE
Intervention: Brachial artery catheter
Description: A catheter will be placed in the brachial artery by a physician on the study day.
Study NCT02123069 — intervention group
Intervention type: DRUG
Intervention: Acetylcholine
Description: Acetylcholine will be infused into the brachial catheter while blood flow levels in the forearm are measured. Acetylcholine will be infused at the following doses: 1.0, 2.0, 4.0, and 8.0 ug/100 ml tissue/min for 2 minutes each.
Study NCT02123069 — intervention group
Intervention type: DRUG
Intervention: Nitroprusside
Description: Nitroprusside will be infused into the brachial catheter while blood flow levels in the forearm are measured. Nitroprusside will be infused at the following doses: 0.25, 0.5, 1.0, and 2.0 ug/100 ml tissue/min for 2 minutes each.
Study NCT02123069 — intervention group
Intervention type: DRUG
Intervention: Norepinephrine
Description: Norepinephrine will be infused into the brachial catheter while blood flow levels in the forearm are measured. Norepinephrine will be infused at the following doses: 1.0, 2.0, 4.0, and 8.0 ug/100 ml tissue/min for 2 minutes each.
Study NCT02123069 — intervention group
Intervention type: DRUG
Intervention: Nitroprusside and phenylephrine
Description: A single dose of nitroprusside (100 ug) will be infused through an IV; one minute later, a single dose of phenylephrine (150 ug) will be infused.
Study NCT04157270 — intervention group
Intervention type: DEVICE
Intervention: Penumbra System
Description: Penumbra System
Study NCT02197169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single intratumoral injection of DNX-2401
Description: In the randomized group, following brain tumor biopsy and histological confirmation of recurrent glioblastoma/gliosarcoma, a single injection of DNX-2401 was administered directly into the brain tumor with or without subsequent interferon gamma (IFN-γ)~No additional subjects will be randomized. A single intratumoral dose of DNX-2401 will be delivered by cannula.
Study NCT02197169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-gamma
Description: In the randomized group, a single injection of DNX-2401 was followed by interferon gamma (IFN-γ). No additional subjects will be randomized or receive IFN-γ following DNX-2401
Study NCT03152227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACGG
Description: 50 high-producing chicks to households along with provision of technical input on production
Study NCT03152227 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ACGG
Description: 50 high-producing chicks to households along with provision of technical input on production
Study NCT03152227 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BCC
Description: Nutrition sensitive BCC on poultry-specific aspects of nutrition, WASH, women's empowerment, and use of income combined with home gardening.
Study NCT02305667 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: King Vision™
Description: double lumen tube intubation using the King Vision™ videolaryngoscope. the distal 21 cm of the left-sided DLT will be bended to replicate the curve of the non-channeled blade and the proximal curve of the DLT remains directed to the right side. Then, after initial 90° clockwise rotation, the bronchial cuff passes through the vocal cords, the stylet of the DLT will be withdrawn and the DLT will be rotated 180°counterclockwise while advancing the DLT to the desired depth.
Study NCT01516710 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open liver resection
Description: Patients will be operated with open liver resection for colorectal metastasis
Study NCT01516710 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic liver resection
Description: Patients will be operated with laparoscopic liver resection
Study NCT04729218 — intervention group
Intervention type: BEHAVIORAL
Intervention: movement imagery ability
Description: Determining the movement imagery ability: internal visual, external visual and kinesthetic imagery
Study NCT02498899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants complete questionnaires at baseline, after watching a video, and after reading a story about the patient in the video.
Study NCT02498899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Participants watch a video lasting about 4 minutes.
Study NCT01318941 — intervention group
Intervention type: DRUG
Intervention: Ranibizumab
Study NCT01318941 — intervention group
Intervention type: OTHER
Intervention: Ranibizumab
Study NCT02686489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heated humidification
Description: Water vapor (molecular water) will be added to the inspired gas of the spontaneously breathing tracheostomy patient by using the Fisher \& Paykel Healthcare, (Auckland, New Zealand) AIRVO 2 Humidification System. The AIRVO 2 will provide respiratory gas flow at 2-60 L/min) that is conditioned to 37° C, 34° C, or 31° C (based on patient comfort) and 100% relative humidity via a heated breathing circuit.
Study NCT02686489 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cool bland aerosol
Description: Aerosol (particles of water suspended in gas) generated by a flow of gas through a pneumatically powered large volume jet nebulizer filled with sterile water (for inhalation) attached to a gas source via a flowmeter set between 10-15 L/min will add moisture to the inspired gas of the spontaneously breathing tracheostomy patient. The cold bland aerosol set-up will consist of corrugated aerosol tubing with one end connected to the nebulizer output port and the other end connected to a tracheostomy mask.
Study NCT03875430 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Humulus lupulus L
Description: Patients with this intervention will receive a dietary supplement to relieve the symptoms of menopause
Study NCT03402178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2082
Description: Solution (0.2 mg) or tablet (0.5 mg and 5 mg).
Study NCT03402178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution (0.2 mg) or tablet (0.5 mg and 5 mg) matched to E2082.
Study NCT01408576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epratuzumab
Description: 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over eight 12-week treatment cycles
Study NCT01408576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epratuzumab
Description: 1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over eight 12 week treatment cycles
Study NCT03820973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief CBT for Anxiety
Description: All participants will receive psychoeducation on anxiety and bCBT treatment approach, work on setting goals, begin self-monitoring, and select skill sessions that fit his/her most pressing needs. Available skills: Relaxation-Diaphragmatic breathing is a simple relaxation technique that increases oxygen flow and reduces the unpleasant physiological sensations associated with anxiety; Exposure - designed to educate Veterans about the role of avoidance in maintaining anxiety problems, as well as information about how to reduce avoidance through exposure exercises; Cognitive - Veterans may opt to address anxiety and worry through modifying negative thinking patterns. Two available options - Increasing Helpful Thoughts and Managing Unhelpful Thoughts.
Study NCT02872337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preoperative Physical Therapy Session
Description: This was a one-on-one preoperative physical therapy session on preoperative education. These patients were also given access to a surgery specific web-based microsite
Study NCT02872337 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Group Preoperative Education Session (per the standard of care)
Study NCT02872337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Preoperative Education Session (per the standard of care)
Study NCT05143086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mouthwash 100% Nano-F
Description: Use 10 ml of mouthwash 100% Nanoencapsulated Fluoride after brushing for one week, twice a day.
Study NCT05143086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mouthwash 50% Nano-F
Description: Use 10 ml of mouthwash 50% Nanoencapsulated Fluoride after brushing for one week, twice a day.
Study NCT05143086 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mouthwash standard
Description: Use 10 ml of mothwash after brushing for one week, twice a day. It's for the positive control of fluoride.
Study NCT05143086 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Use 10 ml of mouthwash without fluoride
Study NCT00078819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept 0.8 mg/kg (up to an intended dose of 50 mg) by subcutaneous injection once a week
Study NCT00078819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to etanercept administered by subcutaneous injection once a week
Study NCT00619619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)
Description: DVS SR Tablets of 10mg, 25mg, 50mg, and 100mg. Assigned DVS SR daily doses of 10mg, 25mg, 50mg, 100mg, or 200mg for up to 8 weeks.
Study NCT04166669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX001
Description: Cohort 1 Day 1: APX001 500 mg IV BID over a 3-hour infusion; Day 18: APX001 500 mg IV BID over a 3-hour infusion. Cohort 2 Day 1: APX001 1000 mg IV BID over a 3-hour infusion; Day 24: APX001 1000 mg IV BID over a 3-hour infusion.
Study NCT04166669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Cohort 1 Days 15-30: itraconazole 200 mg oral solution QD.
Study NCT04166669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Cohort 2 Days 15-33: rifampin 600 mg oral QD.
Study NCT01433952 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Thiamine
Description: Vitamin B1
Study NCT01433952 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01458119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: migalastat hydrochloride
Description: Oral capsule QOD
Study NCT01224756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinoridine HCl
Description: Tinoridine HCl 50 mg, orally, 2 capsules three times daily for up to 4 days.
Study NCT01224756 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tinoridine placebo-matching capsules, orally, 2 capsules three times daily for up to 4 days.
Study NCT02798237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic treadmill training
Description: Participants will receive three sessions per week over 12 weeks, in groups of 2-4 participants, by a trained physiotherapist. The duration of the sessions will be 40 minutes (5-10 minutes of warm-up/cool-down and 30 minutes of aerobic treadmill training at 60-80% of heart rate reserve). The training intensity progression will be individualized.~Before and after the training, participants will remain at rest for 10-15 minutes to measure heart rate, blood pressure and peripheral oxygen saturation (SpO2). The heart rate will be measured continuously during training. Participants will be asked to report any discomfort and to not volunteer to participate in other exercise program. Device: treadmill.
Study NCT02798237 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control (overground walking)
Description: Participants will receive three sessions per week over 12 weeks, in groups of 2-4 participants, by a trained physiotherapist. The duration of the sessions will be 40 minutes (5-10 minutes of warm-up/cool-down and 30 minutes of comfortable walking below 40% of heart rate reserve). Before and after the exercise, participants will remain at rest for 10-15 minutes to measure heart rate, blood pressure and peripheral oxygen saturation (SpO2). The heart rate will be measured continuously. Participants will be asked to report any discomfort and to not volunteer to participate in other exercise program
Study NCT02777853 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green tea
Description: The intervention product is regular green tea brewed with hot water in a large quantity. The tea obtained is dried and the powder, with added sugar, is distributed over sealed aluminium sachets (1 gram of powder per sachet). The product has been cleared for consumption by Unilever's Microbiology Department and the independent Safety and Environmental Assurance Centre of Unilever.
Study NCT02777853 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tea
Description: A product of similar colour and taste, but not the presumed actives of tea (polyphenols), is used as placebo. The product has been cleared for consumption by Unilever's Microbiology Department and the independent Safety and Environmental Assurance Centre of Unilever.
Study NCT01230866 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Proton Radiation Hypofractionation
Description: Dose: 38 Gy(RBE); 7.6 GY(RBE) five days a week in 5 treatments over 1-2 weeks
Study NCT01230866 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Proton Radiation Standard Fractionation
Description: Dose: 79.2 GY(RBE); 1.8 GY(RBE) five days a week in 44 treatments over 8.5-9 weeks
Study NCT00503854 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Ancillary studies
Study NCT03364985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001
Description: DWP16001 tablets